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Abstract—Various novel 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides and their 2-alkylamino derivatives were 
prepared by facile nitrosative cyclization of 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones followed by 
nucleophilic replacement of the 2-methylthio moiety by different amines, and acidic hydrolysis of the 2-methylthio 
moiety afforded the corresponding flavin derivatives. 2-Deoxo-2-methylthio-5-deazaalloxazines and 2-deoxo-2- 
methylthioalloxazine-5-oxides were also prepared by Vilsmeier reaction and by nitrosation of 6-anilino-2- 
methylthiopyrimidin-4(3H)-ones, respectively. Then, they were subjected to nuceleophilic replacement with 
appropriate amines to produce the corresponding 2-alkylamino derivatives. Regiospecific N3-alkylation of 
2-deoxo-2-methylthioalloxazine-5-oxides was carried out with various alkylating agents in the usual way. The 
antitumor activities against CCRF-HSB-2 and KB tumor cells have been investigated in vitro, and many compounds 
showed promising antitumor activities. Furthermore, AutoDock molecular docking into PTK (PDB: 1t46) has been 
done for lead optimization of the aforementioned compounds as potential PTK inhibitors.  
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1. Introduction 
   
Cancer remains as a major threat to the public health. In our previous publications, 1–6 a series of synthesized 
2-phenylflavin-5-oxide and 2-phenyl-5-deazaflavin analogs (Scheme 1) has been reported for their in vitro 
significant antitumor activities against different tumor cell lines. Compounds comprising flavin-N-oxides have been 
recently used for treatments of solid tumors, non-solid tumor masses, leukemia, and non-small cell lung cancers 
involving in situ activator mixed with the flavin-N-oxide for a period of time, results in damage to the DNA in the 
cancer cells without substantial damage to the DNA of normal cells.7 Considering their biological activities, 
6-nitro-5-deazafavin derivatives showed the most potent antitumor activities among the nitro-5-deazafavin 
derivatives.8 The 6- and 8-nitro-5-deazafavin derivatives generating stable one-electron reduction product(s) showed 
marked selective cytotoxicities towards hypoxic cells.9 Furthermore, it has been found that the combination of 
conjugate molecules of 8-amino-5-deazaflavin with the sialosylalkyl group have been found to give rise to 
significant increase in their antitumor activities.10 Nitro-5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules 
were evaluated in vitro as novel DNA targeted bioreductive antitumor agents on KB cells.11  
 
 
 
5-Amino-5-deazaflavins also revealed antiproliferative activity against L1210 and KB tumor cells.12 The 
development of a potent riboflavin antagonist is one of the major interests for the fundamental studies for 
investigation of possible chemotherapeutic activity. Those analogs of riboflavin inhibit flavoenzymes or influence 
riboflavin metabolism in a variety of biological systems provided a reason to prepare a number of isoalloxazines for 
evaluation of their therapeutic activity against cancer.13 Therefore, 8-chloroalloxazine was one of an early series of 
alloxazines and isoalloxazines prepared for the investigation of the possible antitumor activity of riboflavin 
inhibitors.14 And isoalloxazines with a β-hydroxyethyl group at the 9 position as well as some of their esters are also 
designed as riboflavin antagonists, sometimes as antitumor activity.15 Moreover, 6,7-dimethyl-9-formylmethyl- 
isoalloxazine and its thiosemicarbazone analogs were found to be reversible riboflavin antagonists and they showed 
antitumor activity against the Murphy-Sturm lymphosarcoma in rats.13 The 10-aryl-5-deazaflavin derivatives were 
preliminarily reported to act as inhibitors of E3 activity of HMD2 in tumors that retain wide-type P53.16 Some 
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heterocyclic compounds containing a quinoline ring such as 5-deazaflavins are of importance owing to their 
miscellaneous biological activities with higher activity towards tumor cells.17 
Despite of the aforementioned potential antitumor activities of various flavin analogs and the numerous publications 
on chemistry of the related flavin compounds, any information of the 2-methylthio- and 2-alkylamino-flavin analogs 
is none yet without our previous report.18 These circumstances led us to seek a convenient synthetic route to the 
2-methylthio- and 2-alkylamino-flavin analogs to search their potential antitumor activities and to develop potent 
antitumor agents showing a higher selectivity toward tumor cells.  
Thus, in the present paper, we describe a facile synthesis of 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides, which 
were used as versatile intermediates for the synthesis of various 2-alkylamino-2-deoxoflavin-5-oxides by 
nucleophilic substitution involving different primary and secondary alkylamines. Furthermore, they were derived to 
10-alkylflavins and 10-alkylflavin-5-oxide as a novel synthetic route. 2-Deoxo-2-methylthio-5-deazaalloxazines and 
2-methylthioalloxazine-5-oxides were also prepared from 6-anilino-2-methylthiopyrimidin-4(3H)-one. And the 
N3-alkyl analogs of 2-deoxo-2-methylthioalloxazin-5-oxides were prepared by alkylation using various alkylating 
agents. Moreover, 2-deoxo-2-methylthio-5-deazaalloxazines and 2-deoxo-2-methylthioalloxazine-5-oxides were 
subjected to nuceleophilic replacement with some amine derivatives to prepare 2-alkylamino-2-deoxo-5- 
deazaalloxazines and 2-alkylamino-2-deoxoalloxazines, respectively. These compounds were investigated for their 
in vitro antitumor activities. In fact, many of the synthesized compounds showed promising antitumor activities 
against CCRF-HSB-2 and KB tumor cells. The molecular docking study using AutoDock was carried out to get the 
designed compounds possessing higher binding affinities into PTK. As this result, the correlation between the 
growth inhibitory activities (IC50, µg/mL) of the synthesized flavin analogs against tumor cells and the AutoDock 
binding free energies was investigated.  
 
2. Results and discussion 
 
2.1. Chemistry 
The requisite starting material, 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–j) were synthesized by 
treatment of 6-chloro-2-methylthiopyrimidin-4(3H)-one 19,20 with appropriate N-alkyl anilines in n-butanol under 
reflux for 12–72 hours in 55–83% yields.18 The intended 10-alkyl-2-deoxo-2-methylthioflavin-5-oxide (2a–i) were 
prepared by nitrosative cyclization of 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–j) with excess 
NaNO2 in glacial acetic acid at 10–15 °C for 1–2 h to afford the red compounds in 65–89% yields (Scheme 2). The 
preparation of such alkylamino derivatives by reaction of alkylthio derivatives with appropriate amines has long 
been utilized in heterocyclic chemistry. Many of these reactions require rather strenuous conditions and are usually 
carried out in a stainless steel vessel except when amines of high boiling point are used.21 Nucleophilic replacement 
of the methylthio moiety of 10-methyl-2-deoxo-2-methylthioflavin-5-oxides (2a) by dimethylamine in steel sealed 
tube at 160–165 °C (15 kg/cm2 pressure) for 4 h exhibited the replacement accompanied with the N10-demethylation 
and N5-deoxygenation to give 2-deoxo-2-dimethylaminoalloxazine (3), where the singlet signal of the N10-methyl at 
δ 4.1 and 33.5 of 1H-NMR and 13C-NMR, respectively, was lost. Therefore, to avoid the N10-demethylation, this 
reaction should be carried out at lower temperature for short time. Interestingly, facile rapid nucleophilic 
substitution of 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides (2) by different amines was carried out by heating the 
mixture in n-butanol under reflux to afford the yellow crystalline solid of 10-alkyl-2-alkylamino-2-deoxoflavin-5- 
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oxides (4a–e) in 62–89% yields. The pyrimidine moieties of 2a–i to undergo nucleophilic substitution on the carbon 
adjacent to the ring nitrogen are well authenticated and readily explicable in view of the π−electron deficient 
nature.15 Therefore, various aminations were applied for the replacement of 2-methylthio group. The nucleophilic 
substitution of 10-alkyl-2-deoxo-2-methylthioflavin-5-oxide analogs (2) involves short time reaction (15 minutes) in 
comparison with the substitution reaction in case of 2-deoxo-2-methylthio-5-deazflavin analogs, which needs 
reaction time of 2–5 hours.18 In contrast, acidic hydrolysis of 2 by heating in 5N hydrochloric acid under reflux for 
7–12 hours gave the corresponding 10-alkylflavins (5a,b) or 7-methoxy-10-methylflavin-5-oxide (6) as yellow 
needles in 68–97% yields as shown in Scheme 2.  
 
 
 
Another route for synthesis of 10-alkyl-2-alkylamino-2-deoxo-5-deazaflavins (8a,b) was established by the 
nucleophilic substitution of 2-methylthio group of 6-(N-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1a) by an 
appropriate amine before the cyclization of 1a as shown in Scheme 3. This nucleophilic substitution was done either 
by fusion of 1a with n-octylamine of high boiling point or by heating in steel sealed tube at 150–160 °C with 
volatile methylamine. Then, the compounds 7a,b were used as precursors for the preparation of 
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2-alkylamino-2-deoxo-5-deazaflavins (8a,b) by heating with Vilsmeier reagent at 90 °C for three hours, and for the 
preparation of 2-alkylamino-2-deoxoflavin-5-oxides (9a,b) by nitrosative cyclization involving excess NaNO2 in 
glacial acetic acid for 2–3 hours. 
 
 
 
Based on our previous structure based drug design (SBDD) study and docking investigation of different flavin 
analogs, and aiming to discovery of antitumor agents,22 it was concluded from the results considering SAR that the 
higher binding affinities were obtained with the structure features on the flavin or 5-deazaflavin skeleton; NH2 or Ph 
group at the C2-position, H (or alloxazine conformation) or Ph group at the N10-position. Herein, we tried to 
synthesize the designed analogs based on AutoDock possessing higher binding affinities, namely, 2-deoxo-2- 
methylthio-5-deazaalloxazines (12) and 2-deoxo-2-methylthioalloxazine-5-oxides (13). These derivatives can be 
synthesized from the key intermediate, 6-anilino-2-methylthiopyrimidin-4(3H)-ones (11), by facile methods of 
interactions (Scheme 4). The requisite key compounds 11a–e can not be prepared directly from 6-chloro-2- 
methylthiopyrimidin-4(3H)-ones by adapting the same procedure for the preparation of 6-(N-alkylanilino)-2- 
methylthiopyrimidin-4(3H)-ones (1a–j).18 Both of the 6-chloro and 2-methylthio groups were replaced by the 
anilines. Therefore, the compounds 11a–e were prepared in two steps reaction. The first reaction by amine exchange 
route, namely, the reaction of 6-amino-2-thiouracil with anilines in the presence of their corresponding anilinium 
chloride salts at high temperature to afford the corresponding 6-anilino-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidins 
(10a–e) in 67–83% yields. Compounds 10a–e were prepared by modification of known procedure 23,24 to improve 
the yields and to get more pure products. Hence, compound 10a was obtained in higher yield of 83% 
(literatures23,24: 78% and 68% yields). In our proposed procedure, the anilinium chloride derivatives were used in 
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more quantities of 1.5–2.0 equivalents and the crude product was further purified by dissolving it in alkaline 
solution, then reprecipitation by 10% HCl to get more pure compounds. The second step reaction involves 
S-methylation by MeI in alkaline solution in ice bath to afford the 2-methylthio analogs (11a–e) in excellent yields 
of 77–98%. Synthesis of 2-thio-5-deazaalloxazines and 2-thioalloxazine-5-oxides were not successful directly from 
the compounds 10a–e. This may be attributed to oxidative dimerization of the 2-thioxo derivatives. Therefore, the 
2-thioxo moiety should be protected by methylation before the cyclization step to get the desired compounds 12 and 
13. The 2-deoxo-2-methylthio-5-deazaalloxazines (12a,b) were prepared from 11 by Vilsmeier reagent at 90 °C for 
1 h to afford the compounds 12a,b as yellow needles in 72 and 63% yields, respectively. 2-Deoxo-2- 
methylthioalloxazine-5-oxides (13a–e) were also prepared from 11 by nitrosative cyclization using excess NaNO2 in 
glacial acetic acid at 10–15 °C and then at room temperature for 1–2 h. After adding NaNO2 to the cold reaction 
mixture, the formed greenish yellow nitroso intermediates have to be dissolved in acetic acid by mild warming in 
water bath to enhance the prompt cyclization to afford the red products in 66–89% yields (Scheme 4). Moreover, the 
nucleophilic replacement of 2-methylthio group for these compounds 12 and 13 by alkylamines was carried out by 
heating the reaction mixture with appropriate amines in DMF or n-butanol under reflux for high boiling point 
amines (morpholine or N-hydroxyethyl-N-methylamine) for 6–24 hours or in sealing vessel for volatile one 
(dimethylamine) for 8 hours to afford the corresponding yellow crystalline solid of the 2-alkylamino analogs (14a,b 
and 15a,b) in 67–86% yields. This replacement was accompanied by deoxygenation of 2-deoxo-2- 
methylthioalloxazin-5-oxides (13) to produce the 2-alkylamino-2-deoxoalloxazine analogs (15a,b). Interestingly, 
the regiospecific N3-alkylation of 13a–e was carried out using excess alkyl iodide or bromide in the presence of 
anhydrous potassium carbonate in DMF at room temperature to afford the 3-alkyl-2-deoxo-2- 
methylthioalloxazine-5-oxides (16a–e) in 71–82% yields. This alkylation is 100% regioselective at the N3-position, 
giving highly pure one spot product without purification by column chromatography as previously described in 
methylation of 2-deoxo-2-phenyl-5-deazaflavins.6 The discrimination between the positional isomers, 3-methyl-2- 
deoxo-2-methylthioalloxazine-5-oxide (16a) and 10-methyl-2-deoxo-2-methylthioflavin-5-oxide (2a), was 
accurately proved by obvious different melting points and IR spectra where the 4-oxo group of 3-methyl analog 
(16a) was shown at higher frequency of 1700 cm-1, whereas that of 10-methyl analog (2a) was shown at lower 
frequencies 1645 cm-1. In 1H NMR spectra, the N3-methyl of 16a as a singlet signal was shown at 3.64 ppm, while 
the N10-methyl of 2a was shown at lower field of 4.13 ppm. 
UV–Vis, IR, 1H NMR spectra, and elemental analyses, were used for determination and identification of the newly 
assigned structures. The 2-deoxo-2-methylthioflavin-5-oxides (2a–i) were differentiated from the non-cyclized 
compounds (1a–i) by the absence of a singlet signal proton at the 5-position of 1a–i in their 1H NMR spectra and 
loss of one ortho-aromatic proton by the oxidative cyclization. The compounds 2 in UV–Vis spectra revealed the 
characteristic bathochromic shift in the regions of the longest two wavelengths compared with all other flavin 
analogs, as shown in Figure 1 and experimental part. Considering 1H NMR, the spectra of 10-alkyl-2-deoxo-2- 
alkylaminoflavin-5-oxides (4a–e) are characterized by disappearance of the strong characteristic singlet signal of 
2-methylthio group, which was assigned for compounds 2a–i at 2.57–2.60 ppm. Interestingly, the phenomenon of 
reversible interconversion of two isomers at room temperature in case of the 2-monoalkylamino (secondary amino) 
derivatives (4b–e, 8a,b and 9a,b) was observed as tautomerism in 1H NMR spectra as reported the similar 
phenomenon in the previous paper.18 The twin overlapped spectra of approximately 1:2 or 2:1 ratio of the 
2-monoalkylamino and 2-monoalkylimino tautomers in (CD3)2SO were obtained for the two resonance species  
 7 
 
 
(tautomers). Especially, such duplicated spectra were observed in the range of 4.0–9.0 ppm based on the tautomers 
of the guanidine adjacent to the carbonyl group. At higher temperature of 85–100 °C, the coalescence of the 
duplicated spectrum was observed to produce the single spectrum. This phenomenon is mainly attributed to the 
presence of a secondary amine at the 2-position, whereas it does not take place in case of 2-substituted primary and 
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tertiary amines. On the other hand, 2-deoxo-2-methylthio-5-deazaalloxazines (12a,b) showed a characteristic 
singlet signal of the most electron-deficient C5–methine proton in the lower field at 8.98 and 9.16 ppm, 
respectively. 2-Deoxo-2-methylthioalloxazine-5-oxides (13a–e) can be easily differentiated from the 
2-deoxo-2-methylthioflavin-5-oxide analogs (2a–i) by the presence of singlet signals of 3-NH proton at 12.69–12.79 
ppm, whereas such signals of 2a–i were lost. In contrast, the N10-alkyl signals of 2a–i at 4.07–4.19 and 4.77 ppm for 
methyl and methylene moieties were observed, respectively, whereas such signals of 13a–e were none existed. Both 
of them have a singlet signal identified to their 2-SMe moiety at 2.57–2.60 ppm. The 2-alkylamino-2-deoxo-5- 
deazaalloxazines (14a,b) and 2-alkylamino-2-deoxoalloxazines (15a,b) are characterized by disappearance of the 
strong characteristic singlet signals of the 2-methylthio groups of the corresponding precursors (12 and 13) at 
2.44–2.83 ppm. 
The UV–Vis absorption spectra of the 2-deoxo-2-methylthioflavin analogs located at shorter wavelength (nm) in 
comparison with the 2-deoxo-2-phenylflavin analogs6 which have more conjugated system. As shown in Figure 1, 
the 2-deoxo-2-methylthioflavin-5-oxides (2a–i) exhibited four absorption maxima, three in the UV region at 
219–221, 265–289, and 347–370 nm, and one in the visible region at 457–495 nm with bathochromic shift (red 
shift) in the regions of the longest two wavelengths in comparison with the 2-deoxo-2-methylthio-5-deazaflavin 
analogs.18 All compounds of 2a–i showed red color owing to the presence of absorption maximum at 457–495 nm 
in the longest wavelength. The acid hydrolyzed products, 10-alkylflavins (5a,b) exhibited hypsochromic shift 
mainly in the longest two wavelengths in comparison with the UV–Vis spectra of 2a–i as can be shown in Figure 1 
and experimental part. The 2-deoxoflavin-5-oxides (4b–e) substituted by the primary amines at the 2-position 
exhibited four absorption maxima at 217–223, 266–274, 330–350, and 436–453 nm and an additional shoulder at 
472–487 nm as shown in Figure 1 for compound 4b. While, 2-deoxo-2-methylthioalloxazine-5-oxides (13a–e) 
exhibited five absorption maxima at 241–247, 270–275, 285–298, 351–361, and 443–457 nm. 
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2.2. In vitro antitumor activities of different 2–methylthioflavin-5-oxides, alloxazin-5-oxides, 
5-deazaalloxazines, and their 2-alkylamino derivatives against human tumor cell lines 
 
The compounds (2, 4, 6, 8, 9, 12, 13, 15, and 16) synthesized in this study were tested in vitro for their growth 
inhibitory activities against two human cultured tumor cell lines, namely, human T-cell acute lymphoblastoid 
leukemia cell line (CCRF-HSB-2) and human oral epidermoid carcinoma cell line (KB) by using the modified MTT 
colorimetric assay.25 The antitumor agent, cytosine arabinoside (Ara-C) was used as a positive control in this study. 
As can be noticed in Table 1, some compounds of 2-deoxo-2-methylthioflavin-5-oxides (2), 2-deoxo-2- 
alkylaminoflavin-5-oxides (4), flavin-5-oxides (6), and 2-deoxo-2-alkylamino-5-deazaflavins (8) have been found to 
show significant antitumor activities, but they were of inferior antitumor activities than that of Ara-C against 
CCRF-HSB-2 cell line. The activities for the compounds (2a,d, 4e, 5a,b, 8a, and 9a) were the highest among their 
analogs (IC50: 1.56, 1.46, 1.46, 1.8, 1.57, 2.7, and 1.74 µg/mL, respectively). Further, against KB cell line they 
exhibited good growth inhibitory activities of one third to one ninth against the antitumor potency of Ara-C (IC50: 
0.23 µg/mL), where IC50 of compounds 2a,d, 4e, and 5a,b were of 1.44, 0.61, 1.7, 2.1, and 1.89 µg/mL, 
respectively. This may reveal a fairly good and less toxic antitumor activity of these flavin analogs in comparison 
with Ara-C. Moreover, compounds 2b,g, 4b,c, and 6 exhibited moderate potential growth inhibitory activities 
against CCRF-HSB-2 cell line with IC50 of 3.72, 6.66, 6.0, 7.1, and 5.1 µg/mL, respectively. Also compounds 2b, 
4b, and 6 exhibited prospective growth inhibitory activities against KB cell line of IC50 being 8.19, 8.1, and 6.2 
µg/mL, respectively.  
 
In comparison with the antitumor activities of the above studied flavin-5-oxide, 2-alkylaminoflavin-5-oxide, and 
5-deazaflavin derivatives (2, 4, 5, and 8), which revealed the IC50 in the range of 1.46–2.7 and 0.61–2.1 µg/mL 
against CCRF-HSB-2 and KB tumor cell lines, respectively, and the activities of our previously reported potent 
2-deoxo-2-phenylflavin analogs,6 which revealed the IC50 in the range of 0.15–0.68 µg/mL for CCRF-HSB-2 cells 
and 0.16–0.72 µg/mL for KB cells. It can be explained that the phenyl group at the C2-position provides better 
affinity to the PTK enzyme on account of the force of electrostatic attraction between the planar phenyl and the target 
site pocket of the PTK. Hence, the phenyl derivatives exhibit a good fitting into the active site and better antitumor 
activity. The results considering SAR revealed that the highest antitumor activities (ca. 1.5 µg/mL) were obtained 
with the structure features on the flavin-5-oxide, 5-deazaflavin, and alloxazine skeletons; SMe or HNMe group at the 
C2-position, H (or alloxazine conformation) or Me group at the N10-position, and unsubstituted quinoxaline nucleus 
or substituted by 7-Me, or 9-Me group. The SAR revealing moderate antitumor activity (ca. 5.5 µg/mL) was obtained 
with the structure features: HN-n-Bu or oxo at the C2-position, Me or Et group at the N10-position, and unsubstituted 
quinoxaline nucleus or substituted by 7-OMe group. Noteworthy, the N3-alkyl substituted alloxazin-5-oxides 
exhibited lower antitumor activities than their unsubstituted analogs as shown in Table 1. And the N-5-oxide analogs 
revealed higher potencies than those of 5-deazaflavins. These results confirm our previously reported SAR study.22  
 
2.3. Molecular docking study 
Due to their involvement in various forms of cancers, PTKs have become prominent targets for therapeutic 
intervention. The selective PTK inhibitors into the receptor and non-receptor PTK represent a promising class of 
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antitumor agents. These agents are shown to inhibit multiple features of cancer cells, including proliferation, 
survival, invasion, and angiogenesis. Depending on the above-mentioned idea, herein we investigated the AutoDock 
binding affinities into PTK (PDB code, 1t46) for the synthesized flavin analogs (2–6, 8, 9, and 12–16). For the 
purpose of optimization of the aforementioned lead compounds for the promising antitumor activities, the advanced 
docking program AutoDock 3.05 26 was used to evaluate the binding free energies of these inhibitors into the target 
PTK macromolecule. 
 
2.3.1. Validation of the docking performance and accuracy 
The validation of the docking accuracy was done by docking of the native co-crystallized STI-571 ligand (Imatinib 
or Gleevec), 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]- 
benzamide, into its binding site of PTK. The obtained success rates of AutoDock, as mentioned in detail in our 
previous paper,18 was highly excellent in comparison with the biological method27 Where, the docked ligand was 
 11 
exactly superimposed on the native co-crystallized one with RMSD being 0.25 Å and binding free energies (ΔGb) 
of –18.43 kcal/mol. The hydrogen bonds exhibited between the docked ligand and amino acids were quite same to 
them between the native ligand and amino acids.  
 
 
 
2.3.2. AutoDock binding affinities of the synthesized and the designed compounds into PTK 
The binding affinity was evaluated by the binding free energies (ΔGb, kcal/mol), inhibition constants (Ki), hydrogen 
bonds, and RMSD values. The compounds, which revealed the highest binding affinities (in other words, lowest 
binding free energies) within PTK and the hydrogen bond interactions into the target macromolecule, are 
represented in Table 2. These compounds include 2-dimethylamino-2-deoxoalloxazine (3), 10-alkyl-2-alkylamino- 
2-deoxoflavin-5-oxides (4b–e), 2-alkylamino-10-methyl-5-deazaflavins (8a,b), 2-alkylamino-2-deoxo-10-methyl- 
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flavin-5-oxides (9a,b), 2-methylthioalloxazine-5-oxides (13c,d), and 3,7,9-trimethyl-2-methylthioalloxazine- 
5-oxide (16b). Compounds 2-(2-hydroxyethylamino)-7,10-dimethyl-2-deoxoflavin-5-oxide (4e) and 10-methyl-2- 
methylamino-2-deoxoflavin-5-oxide (9a) as shown in Figure 2 and 3, respectively, were deeply embedded into the 
catalytic and activation loops of the ATP-binding cleft of the c-Kit receptor tyrosine kinase domain with ΔGb: 
–13.76 for 4e and –12.75 kcal/mol for 9a. Compounds 4e showed two hydrogen bonds with Asp 810 and Glu 640, 
whereas 9a showed one hydrogen bond with Thr 679. These docking results of compounds 4e and 9a are highly 
correlated to their antitumor activities cited in Table 1. 
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Figure 4 illustrates the comparative docking modes of 8a and 13d into the c-Kit receptor PTK together with the 
bound ligand STI. Compounds 8a (ΔGb: –13.01 kcal/mol) and 13d (ΔGb: –8.95 kcal/mol) were docked into same 
groove of the binding site along with STI-ligand and exhibited two (with Glu 640 and Asp 810) and one (with Asp 
810) hydrogen bonds, respectively.  
 
 
 
Figure 2. Stereo view of compound 2-(2-hydroxyethylamino)-7,10-dimethyl-2-deoxoflavin-5-oxide (4e) (ball and 
stick, colored by element) deeply embedded into the ATP-binding cleft of the c-Kit receptor PTK domain with the 
bound ligand STI-571. Hydrogen bonds are shown as green dashed lines. 
Figure 3. Docking of compound 2-methylamino-2-deoxo-10-methylflavin-5-oxide (9a) (ball and stick, colored by 
element) into the ATP-binding cleft of the c-Kit receptor PTK, exhibiting one hydrogen bond with amino acid Thr 
670 (in green dashed lines) and RMSD being 6.40 Å from the bound ligand STI-571. 
Figure 4. AutoDock binding affinities of compound 2-deoxo-2-methylamino-5-deazaflavin (8a; colored by element, 
ball and stick) and 2-deoxo-7-methyl-2-methylthioalloxazine-5-oxide (13d; red, stick) into PTK (1t46). They 
exhibit two and one hydrogen bonds, respectively, shown as green dashed lines. The binding pocket of the PTK is 
shown in transparent solid surface with labeled amino acids and the STI ligand is shown as yellow stick. 
 
The docking for 2-deoxo-2-methylthioflavin-5-oxides (2), flavins (5), and flavin-5-oxide (6) exhibited mostly 
higher binding energies (lower binding affinities) being –9.11 to –7.43 kcal/mol (ΔGb) due to less proper fitting into 
the target site by hydrogen bond formation, in comparison with the binding energies of other derivatives (3, 4, 8, 
and 9) (ΔGb: –14.83 to – 12.75 kcal/mol). However, some compounds showed better antitumor activities in spite of 
the lower binding affinities as cited in Table 1. It appeared reasonable to conclude the reason for the better 
antitumor activities as described below.  That is, the planar pyrimidoquinoxaline ring of compounds 2, 5, and 6 
was involved in hydrophobic electrostatic surface interaction, where it was sandwiched within distance of ca. 5.0 Å 
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between the phenyl moieties of Phe 811 and Tyr 672 and the terminal hydrocarbon chain of Leu 595. Also their 
2-methylthio group interacts with Leu 644, Val 654, Val 668, and Cys 809 by hydrophobic attraction within 
distance of ca. 3.62–5.16 Å. This interaction keeps these derivatives (2, 5, and 6) in the binding site, within RMSD 
values of 4.09–6.53Å. 
The overall correlation between the growth inhibitory activities of the synthesized flavin analogs against tumor cells 
and the AutoDock binding affinities was better for some compounds. The growth inhibitory activities of compounds 
2c,h, 4a–c,e, 8a,b, 9a, 12a, and 16d against CCRF-HSB-2 tumor cells were correlated to their AutoDock binding 
free energies with a good correlation coefficient (R2) of 0.759 as shown in Figure 5 . 
 
 
 
 
Whereas, the growth inhibition against KB tumor cells revealed a reasonable correlation with Autodock binding free 
energies for compounds 2e,f,g, 4b,e, 8b, 9a, 13b, and 16b,c,e of correlation coefficient (R2) of 0.68 as shown in 
Figure 6. 
  
 15 
 
 
3. Conclusions 
 
In this study, various novel 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides (2a–i) were synthesized from 
6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–i) by nitrosative cyclization. The 2-alkylamino 
derivatives (4a–e) were synthesized by the facile replacement of the C2-methylthio moiety of 2 by different amines. 
Flavins  (5a,b) and flavin-5-oxide (6) were prepared by acidic hydrolysis of 2 in excellent yields. Nucleophilic 
substitution of 2-methylthio group of the non-cyclized 6-(N-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1a) 
by an appropriate amine was carried out, followed by Vilsmeier reaction to afford the 2-alkylamino-2-deoxo- 
5-deazaflavins (8a,b) or by nitrosative cyclization to afford the 2-alkylaminoflavin-5-oxides (9a,b). Compounds 
2-deoxo-2-methylthio-5-deazaalloxazines (12) and 2-deoxo-2-methylthioalloxazine-5-oxides (13) were facilely 
synthesized from 6-anilino-2-methylthiopyrimidin-4(3H)-ones (11) by Vilsmeier reaction and nitrosative cyclization, 
respectively. The nucleophilic replacement of 2-methylthio group of compounds (12 and 13) was carried out by 
heating with alkylamines to afford their 2-alkylamino analogs (14 and 15). Additionally, 3-alkyl-2- 
methylthioalloxazine-5-oxides (16a–e) were prepared by the regiospecific N3-alkylation of 2-deoxo-2- 
methylthioalloxazine-5-oxides (13) using excess alkyl iodide or bromide.  
In vitro growth inhibitory activities of compounds (2, 4, 6, 8, 9, 12, 13, 15, and 16) against T-cell acute 
lymphoblastoid leukemia cell line (CCRF-HSB-2) and human oral epidermoid carcinoma cell line (KB) revealed 
potential antitumor activities of many derivatives. Among them, compounds 2a, 2d, 4e, 5a, 5b, 8a, and 9a exhibited 
the most significant antiproliferative potencies with good IC50 of 1.46–2.70 and 0.61–2.1 µg/mL against 
CCRF-HSB-2 and KB cells, respectively. Some other derivatives, namely 2b, 4b, 6, 13a, 13c and 13d, showed 
moderate IC50 of 3.72–6.77 and 5.35–8.19 µg/mL against CCRF-HSB-2 and KB cells, respectively. These 
promising antitumor activities provide these derivatives as new lead entities in cancer therapy. Moreover, the 
structure-activity relationships (SAR) revealed that the flavin-5-oxide, 5-deazaflavin, and alloxazine skeletons with 
SMe or HNMe group at the C2-position, alloxazine conformation or Me group at the N10-position, and unsubstituted 
quinoxaline nucleus or substituted by 7-Me or 9-Me group provide higher antitumor activities.  
The AutoDock investigation of the synthesized derivatives (2–6, 8, 9, and 12–16) was carried out for lead 
optimization and they docked into c-kit protein tyrosine kinase. The correlation between the binding free energies 
(ΔGb, kcal/mol) predicted by AutoDock and the growth inhibitory activities (IC50, µg/mL) against CCRF-HSB-2 
tumor cells for compounds 2c,h, 4a–c,e, 8a,b, 9a, 12a, and 16d was good correlation coefficient (R2) of 0.759. Also 
the correlation between and the AutoDock binding free energies and IC50 against KB tumor cells for compounds 
2e,f,g, 4b,e, 8b, 9a, 13b, and 16b,c,e was good correlation coefficient (R2) of 0.68.  
 
4. Experimental 
4.1. Chemistry 
 
Mps were obtained on a Yanagimoto micro melting point apparatus and were uncorrected. Microanalyses were 
measured by Yanaco CHN Corder MT-5 apparatus. IR spectra were recorded on a JASCO FT/IR-200 spectro- 
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photometer as Nujol mulls. 1H NMR spectra were obtained using a Varian VXR 300 MHz spectrophotometer and 
chemical shift values were expressed in δ values (ppm) relative to tetramethylsilane (TMS) as internal standard. 
Coupling constants are given in Hz. All NH and OH protons were exchangeable with D2O. UV spectra were 
measured in absolute EtOH using Beckman DU-68S UV spectrophotometer and absorption values followed by sh 
refer to wave lengths at which shoulders or inflexions occur in the absorption. All reagents were of commercial 
quality and were used without further purification. Organic solvents were dried in the presence of an appropriate 
drying agent and were stored over suitable molecular sieves. Reaction progress was monitored by analytical thin 
layer chromatography (TLC) on pre-coated glass plates (silica gel 60F254-plate-Merck) and the products were 
visualized by UV light. 
 
4.1.1 General procedure for the preparation of 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides {10-alkyl-2- 
methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxides} (2a–i). To a stirring solution of 
6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-one (1, 0.01mol) in acetic acid (5–15 mL) at 10–15 °C was added 
sodium nitrite (0.02–0.04 mol) by portions, and the mixture was stirred for 1–2 h at room temperature. The solid 
deposited was collected by suction filtration and washed with water. The filtrate was evaporated in vacuo and 
diluted with excess water to afford the second crop. The collected solids were dried and crystallized from an 
appropriate solvent to afford the corresponding products as red needles in 65–89% yields. 
 
4.1.2.  10-Methyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2a). Yield, (2.0 g, 73%); mp 
215–217 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 (4.53), 269 (4.39), 368 (4.00), 
464 (4.09); IR (νmax/cm-1): 1650 (C=O); 1H NMR (CDCl3): δ 2.59 (3H, s, 2-SMe), 4.13 (3H, s, 10-Me), 7.60 (1H, dt, 
J6,7 = J7,8 = 8.7 Hz, J7,9 = 1.5 Hz, 7-H), 7.75 (1H, dd, J7,9 = 1.5 Hz, J8,9 = 8.7 Hz, 9-H), 7.94 (1H, dt, J7,8 = J8,9 = 8.7 
Hz, J6,8= 1.5 Hz, 8-H), 8.57 (1H, dd, J6,7 = 8.7 Hz, J6,8 = 1.5 Hz, 6-H); Anal. calcd for C12H10N4O2S: C, 52.54; H, 
3.67; N, 20.43. Found: C, 52.61; H, 3.91; N, 20.59.  
 
4.1.3.  10-Ethyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2b). Yield, (2.57 g, 89%); mp 
234–236 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.53), 278 (4.38), 371 (4.06), 
468 (4.16); IR (νmax/cm-1): 1655 (C=O); 1H NMR (CDCl3): δ 1.53 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 2.59 (3H, s, 
2-SMe), 4.77 (2H, q, J = 7.2 Hz, 10-CH2-CH3), 7.60 (1H, dt, J6,7 = 8.7Hz, J7,8 = 8.4 Hz, J7,9 = 1.5 Hz, 7-H), 7.74 (1H, 
br d, J8,9 = 8.4 Hz, 9-H), 7.94 (1H, dt, J7,8 = J8,9 = 8.4 Hz, J6,8= 1.5 Hz, 8-H), 8.58 (1H, dd, J6,7 = 8.7Hz, J6,8 = 1.5 Hz, 
6-H); Anal. calcd for C13H12N4O2S: C, 54.15; H, 4.19; N, 19.43. Found: C, 54.31; H, 4.38; N, 19.16.  
 
4.1.4.  7,10-Dimethyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2c). Yield, (2.02 g, 70%); 
mp 221–223 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.48), 279 (4.38), 369 
(4.00), 472 (4.11); IR (νmax/cm-1): 1650 (C=O); 1H NMR (CDCl3): δ 2.57 (3H, s, 7-Me), 2.59 (3H, s, 2-SMe), 4.11 
(3H, s, 10-Me), 7.63 (1H, d, J8,9 = 8.4 Hz, 9-H), 7.75 (1H, dd, J8,9 = 8.4 Hz, J6,8 = 2.1 Hz, 8-H), 8.35 (1H, br s, 6-H); 
Anal. calcd for C13H12N4O2S: C, 54.15; H, 4.19; N, 19.43. Found: C, 54.15; H, 4.26; N, 19.12. 
 
4.1.5.  9,10-Dimethyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2d). Yield, (2.05 g, 71%); 
mp 200–202 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 (4.55), 268 (4.47), 377 
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(4.10), 466 (4.04); IR (νmax/cm-1): 1650 (C=O); 1H NMR (CDCl3): δ 2.58 (3H, s, 2-SMe), 2.88 (3H, s, 9-Me), 4.19 
(3H, s, 10-Me), 7.47 (1H, t, J6,7 = J7,8 = 8.1 Hz, 7-H), 7.69 (1H, d, J7,8 = 8.1 Hz, 8-H), 8.42 (1H, d, J6,7 = 8.1 Hz, 
6-H); Anal. calcd for C13H12N4O2S: C, 54.15; H, 4.19; N, 19.43. Found: C, 54.47; H, 4.49; N, 19.39. 
 
4.1.6.  7-Methoxy-10-methyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2e). Yield, (2.37 g, 
78%); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.66), 289 (4.61), 365 (4.14), 
and 495 (4.28); IR (νmax/cm-1): 1640 (C=O); 1H NMR (CDCl3): δ 2.59 (3H, s, 2-SMe), 3.98 (3H, s, 7-OMe), 4.14 
(3H, s, 10-Me), 7.56 (1H, dd, J8,9 = 9.3 Hz, J6,8 = 2.7 Hz, 8-H), 7.69 (1H, d, J8,9 = 9.3 Hz, 9-H), 7.96 (1H, d, J6,8 = 2.7 
Hz, 6-H); Anal. calcd for C13H12N4O3S: C, 51.31; H, 3.97; N, 18.41. Found: C, 51.19; H, 4.10; N, 18.32. 
 
4.1.7.  8-Methoxy-10-methyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2f). Yield, (2.04 g, 
67%); mp 214–217 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 228 (4.50), 265 (4.34), 
379 (4.26), 457 (4.23); IR (νmax/cm-1): 1630 (C=O); 1H NMR (CDCl3): δ 2.57 (3H, s, 2-SMe), 4.06 (3H, s, 8-OMe), 
4.07 (3H, s, 10-Me), 6.96 (1H, d, J7,9 = 2.4 Hz, 9-H), 7.14 (1H, dd, J6,7 = 9.6 Hz, J7,9 = 2.4 Hz, 7-H), 8.45 (1H, d, J6,7 
= 9.6 Hz, 6-H); Anal. calcd for C13H12N4O3S: C, 51.31; H, 3.97; N, 18.41. Found: C, 51.28; H, 4.40; N, 18.40. 
 
4.1.8.  7-Chloro-10-methyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2g). Yield, (2.0 g, 
65%); mp 303–305 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.39), 268 (4.34), 
347 (4.72), 469 (3.85); IR (νmax/cm-1): 1660 (C=O); 1H NMR (CDCl3): δ 2.60 (3H, s, 2-SMe), 4.10 (3H, s, 10-Me), 
7.68 (1H, d, J8,9 = 9.6 Hz, 9-H), 7.87 (1H, dd, J8,9 = 9.6 Hz, J6,8 = 2.4 Hz, 8-H), 8.54 (1H, d, J6,8 = 2.4 Hz, 6-H); Anal. 
calcd for C12H9ClN4O2S: C, 46.68; H, 2.94; N, 18.15. Found: C, 46.89; H, 3.09; N, 17.88. 
 
4.1.9.  10-Ethyl-7-methyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2h). Yield, (2.6 g, 
86%); mp 236–238 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.45), 273 (4.31), 
368 (3.87), 470 (3.93); IR (νmax/cm-1): 1650 (C=O); 1H NMR (CDCl3): δ 1.51 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 2.57 
(3H, s, 7-Me), 2.59 (3H, s, 2-SMe), 4.76 (2H, q, J = 7.2 Hz, 10-CH2-CH3), 7.68 (1H, d, J8,9 = 9.0 Hz, 9-H), 7.75 (1H, 
dd, J8,9 = 9.0 Hz, J6,8 = 1.5 Hz, 8-H), 8.37 (1H, br s, 6-H); Anal. calcd for C14H14N4O2S: C, 55.61; H, 4.67; N, 18.53. 
Found: C, 55.33; H, 4.79; N, 18.16. 
 
4.1.10.  7,8,10-Trimethyl-2-methylthio-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (2i). Yield, (2.45 g, 
81%); mp >300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 (4.64), 280 (4.59), 
378 (4.29), 474 (4.35); IR (νmax/cm-1): 1650 (C=O); 1H NMR (CDCl3): δ 2.52 (3H, s, 7-Me), 2.53 (3H, s, 8Me), 2.57 
(3H, s, 2-SMe), 4.10 (3H, s, 10-Me), 7.49 (1H, s, 6-H), 8.21 (1H, s, 9-H); Anal. calcd for C14H14N4O2S: C, 55.61; H, 
4.67; N, 18.53. Found: C, 55.85; H, 4.68; N, 18.38. 
 
4.1.11.  Preparation of 2-deoxo-2-dimethylaminoalloxazine {2-dimethylamino-4-oxo-3,4-dihydrobenzo[g]- 
pteridine} (3). A mixture of 2-deoxo-10-methyl-2-methylthioflavin-5-oxide (2a, 1.4 g, 5.0 mmol) and 50% aqueous 
dimethylamine (50 mL) was heated in steel sealed tube at 160–165 °C (15 kg/cm2 pressure) for 4 h. After the 
reaction was complete, the precipitated crystals were collected by filteration, and mother liquor was evaporated in 
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vacuo to get the second crop. The product was washed with water, dried and recrystallized from EtOH to afford the 
yellow crystals in 89% yield. 
Yield, (1.07 g, 89%); mp >300 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 (4.39), 
268 (4.32), 288 (4.32), 335 (3.63), 376sh (3.59), 398 (3.71), 429 (3.77); IR (νmax/cm-1): 3190 (NH), 1700 (C=O); 1H 
NMR (CDCl3): δ 3.42 (6H, s, 2-N-(CH3)2), 7.66 (1H, dt, J6,7 = J7,8 = 8.4 Hz, J7,9 = 1.5 Hz, 7-H), 7.81 (1H, dt, J7,8 =  
J8,9 = 8.4 Hz, J6,8 = 1.5 Hz, 8-H), 8.04 (1H, br d, J8,9 = 8.4 Hz, 9-H), 8.23 (1H, br d, J6,7 = 8.4 Hz, 6-H), 10.13 (1H, br 
s, 3-NH, exchangeable with D2O); Anal. calcd for C12H11N5O· 0.2H2O: C, 58.86; H, 4.69; N, 28.60. Found: C, 
58.78; H, 4.87; N, 28.58. 
 
4.1.12.  General procedure for the preparation of 10-alkyl-2-alkylamino-2-deoxoflavin-5-oxides {10-alkyl- 
2-alkylamino-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxides} (4a–e). A mixture of 
10-alkyl-2-deoxo-2-methylthioflavin-5-oxides (2, 5.0 ｍmol) and an appropriate alkylamine (0.025–0.05 mol) in 
n-butanol (30 mL) was refluxed with stirring for 15 min. After the clear yellow solution obtained under reflux was 
cooled under refrigeration overnight, the resulting yellow crystals were collected by filtration to get the first crop. 
The filtrate was concentrated in vacuo and the residue was treated with ethanol or water to get the second crop free 
from amines. The collected solids were dried and recrystallized from an appropriate solvent to give the 
corresponding products as bright yellow-orange needles in 62–89% yields. 
 
4.1.13.  7-Methoxy-10-methyl-2-piperidino-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (4a). Yield, (1.06 g, 
62%); mp 276–278 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 223 (4.37), 266 (4.28), 
284 (4.48), 350 (3.88), 444sh (3.95), 476 (4.17), 506 (4.14); IR (νmax/cm-1): 1645 (C=O); 1H NMR (CDCl3): δ 1.66 
(2H, br s, 4'-CH2), 3.74–3.80 (4H, ｍ, 3' and 5'-CH2), 3.92 (3H, s, 7-OMe), 4.04–4.12 (4H, m, 2' and 6'-CH2), 4.09 
(3H, s, 10-Me), 7.47 (1H, dd, J8,9 = 9.3 Hz, J6,8 = 2.7 Hz, 8-H), 7.56 (1H, d, J8,9 = 9.3 Hz, 9-H), 7.75 (1H, d, J6,8 = 2.7 
Hz, 6-H); Anal. calcd for C17H19N5O3: C, 59.81; H, 5.61; N, 20.52. Found: C, 59.58; H, 5.44; N, 20.75. 
 
4.1.14.  10-Ethyl-2-isobutylamino-4-oxo-4,10-dihydrobenzo[g]pteridin-5-oxide (4b). Yield, (1.30 g, 83%); mp 
264–267 °C (decomp., from EtOH-n-hexane); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 (4.47), 271 (4.47), 
343sh (3.96), 443 (3.12), 472sh (3.98); IR (νmax/cm-1): 3195 (NH), 1620 (C=O); 1H NMR (CDCl3): δ 0.99–1.02 (6H, 
m, NH-CH2-CH-(CH3)2), 1.46–1.56 (3H, m, 10-CH2-CH3) 1.92–2.08 (1H, m, NH-CH2-CH-(CH3)2), 3.44–3.51 (2H, 
m, NH-CH2-CH-(CH3)2), 4.75 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 5.75 (1H, br s, 2-NH, exchangeable with D2O), 
7.53–7.65 (2H, m, 7 and 9-H), 7.76–7.88 (1H, m, 8-H), 7.32–7.40 (1H, m, 6-H); Anal. calcd for C16H19N5O2: C, 
61.33; H, 6.11; N, 22.35. Found: C, 61.51; H, 6.44; N, 22.43. 
 
4.1.15.  2-Cyclohexylamino-7,10-dimethyl-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (4c). Yield, (1.05 g, 
62%); mp 288–291 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.56), 271 (4.57), 
341 (3.94), 436 (4.10), 483sh (3.83); IR (νmax/cm-1): 3270 (NH), 1665 (C=O); 1H NMR [(CD3)2SO], 100 °C: δ 
1.10–1.68 (6H, m, 3', 4', and 5'-CH2), 1.68–1.98 (4H, m, 2' and 6'-CH2), 2.49 (3H, s, 7-Me), 3.95 (3H, s, 10-Me), 
4.02–4.06 (1H, br m, 1'-CH), 7.37 (1H, br s, 2-NH, exchangeable with D2O), 7.67–7.78 (1H, m, 9-H), 7.87 (1H, br s, 
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6-H), 7.95 (1H, br d, J8,9 = 9.0 Hz, 8-H); Anal. calcd for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found: C, 63.99; 
H, 6.34; N, 20.25. 
 
4.1.16.  2-Benzylamino-7-chloro-10-methyl-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (4d). Yield, (1.34 g, 
73%); mp >300 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.85), 274 (4.90), 330 (4.24), 
453 (4.38), 487sh (4.24); IR (νmax/cm-1): 3190 (NH), 1655 (C=O); 1H NMR [(CD3)2SO], at 100 °C: δ 4.00 (3H, s, 
10-Me), 4.60–4.80 (2H, m, 2-NH-CH2), 7.20–7.52 (5H, m, 2-CH2-C6H5), 7.82–8.02 (2H, m, 2-NH and 9-H), 
8.10–8.28 (2H, m, 6 and 8-H); Anal. calcd for C18H14ClN5O2· 0.25H2O: C, 58.07; H, 3.93; N, 18.81. Found: C, 
57.89; H, 4.28; N, 18.42. 
 
4.1.17.  2-(2-Hydroxyethylamino)-7,10-dimethyl-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (4e). Yield, 
(1.34 g, 89%); mp 266–268 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 217 (4.62), 
273 (4.64), 344 (4.12), 453 (4.24), 483sh (4.11); IR (νmax/cm-1): 3290 (OH), 3200 (NH), 1660 (C=O); 1H NMR 
[(CD3)2SO], at 100 °C: δ 2.49 (3H, s, 7-Me), 3.38–3.46 (2H, m, 2-NHCH2CH2OH), 3.48–3.60 (2H, m, 
2-NHCH2CH2OH), 3.97 (3H, s, 10-Me), 4.86 (1H, br s, 2-NHCH2CH2OH, exchangeable with D2O), 7.42 (1H, br s, 
2-NH, exchangeable with D2O), 7.70–7.81 (1H, m, 9-H), 7.85–7.97 (2H, m, 6 and 8-H); Anal. calcd for C14H15N5O3: 
C, 55.81; H, 5.02; N, 23.24. Found: C, 56.04; H, 4.95; N, 23.34. 
 
4.1.18.  General procedure for the preparation 10-alkylflavins {10-alkylbenzo[g]pteridine-2,4(3H,10H)- 
diones} (5a,b) and 7-methoxy-10-methylflavin-5-oxide {7-methoxy-10-methyl-2,4-dioxo-2,3,4,10-tetrahydro- 
benzo[g]pteridine-5-oxide (6). To 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides (2, 0.01 mol) was added 5N 
hydrochloric acid (250 mL). Then, the mixture was refluxed for 7–12 hours, and the resulting clear yellow solution 
was concentrated in vacuo. The yellow residue was treated with water and neutralized with aqueous ammonia (pH 
7). The precipitate powdery crystals were filtered off, washed well with water, dried and recrystallized from acetic 
acid to afford the corresponding products as yellow needles in 68–97% yields. 
 
4.1.19.  10-Methylbenzo[g]pteridine-2,4(3H,10H)-dione (5a). Yield, (2.05 g, 90%); mp >300 °C (from HOAc; 
lit.28 m.p. >360 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 214 (4.31), 265 (4.39), 332 (3.74), 436 (3.81); IR 
(νmax/cm-1): 3170 (NH), 1720, 1660 (C=O); 1H NMR [(CD3)2SO]: δ 3.98 (3H, s, 10-Me), 7.62–7.69 (1H, m, 7-H), 
7.93–7.98 (2H, m, 8 and 9-H), 8.13 (1H, br d, J6,7 = 7.8 Hz, 6-H), 11.10 (1H, br s, 3-NH, exchangeable with D2O); 
Anal. calcd for C11H8N4O2· 0.6H2O: C, 55.28; H, 3.88; N, 23.44. Found: C, 55.47; H, 3.70; N, 23.02. 
 
4.1.20.  10-Ethylbenzo[g]pteridine-2,4(3H,10H)-dione (5b). Yield, (2.35 g, 97%); mp >300 °C (from HOAc; 
lit.28 m.p. 347 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 216 (4.53), 265 (4.65), 335 (3.98), 434 (4.13); IR 
(νmax/cm-1): 3180 (NH), 1720, 1680 (C=O); 1H NMR (CDCl3): δ 1.33 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 4.65 (2H, q, 
J = 7.2 Hz, 10-CH2-CH3), 7.65 (1H, d t, J6,7 = J7,8 = 7.8 Hz, J7,9 = 1.2 Hz, 7-H), 7.92–8.03 (2H, m, 8 and 9-H), 8.14 
(1H, dd, J6,7 = 7.8 Hz, J6,8 = 1.2 Hz, 6-H), 11.39 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for 
C12H10N4O2: C, 59.50; H, 4.16; N, 23.13. Found: C, 59.10; H, 4.40; N, 23.06. 
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4.1.21.  7-Methoxy-10-methyl-2,4-dioxo-2,3,4,10-tetrahydrobenzo[g]pteridine-5-oxide (6). Yield, (1.86 g, 
68%); mp >300 °C (from HOAc); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 216 (4.57), 272 (4.63), 339 (4.04), 
474 (4.18); IR (νmax/cm-1): 3160 (NH), 1710, 1665 (C=O); 1H NMR [(CD3)2SO]: δ 3.93 (3H, s, 7-OMe), 3.99 (3H, s, 
10-Me), 7.59 (1H, d, J6,8 = 3.0 Hz, 6-H), 7.63–7.65 (1H, m, 8-H), 7.91(1H, d, J8,9 = 9.0 Hz, 9-H), 11.03 (1H, br s, 
3-NH, exchangeable with D2O); Anal. calcd for C12H10N4O4: C, 52.56; H, 3.68; N, 20.43. Found: C, 52.87; H, 3.94; 
N, 20.13. 
 
4.1.22.  Preparation of 2-methylamino-6-(N-methylanilino)pyrimidin-4(3H)-one (7a). A mixture of 
6-(N-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1a, 0.5 g, 2.0 mmol) and 40% aqueous methylamine (50 
mL) in steel sealed tube was heated at 160 °C (10 kg/cm2 pressure) for 15 h. After the reaction was complete, the 
resulting clear yellow solution was concentrated in vacuo. The yellow residue was treated with ethyl acetate to get 
the solid, which was filtered off, washed with water, dried and crystallized from DMF to afford the pure product as 
colorless needles. 
Yield, (0.40 g, 87%); mp 219–221 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 229 (4.49), 258sh 
(4.15), 284 (4.21); IR (νmax/cm-1): 3310, 3176 (NH), 1625 (C=O); 1H NMR (CDCl3): δ 2.88 (3H, s, 2-NMe), 3.44 
(3H, s, 6-NMe), 4.67 (1H, s, 5-H), 5.52 (1H, br s, 2-NH, exchangeable with D2O), 7.01–7.44 (5H, ｍ, Ph-H), 12.19 
(1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C12H14N4O: C, 62.59; H, 6.13; N, 24.33. Found: C, 62.23; 
H, 6.07; N, 24.33. 
 
4.1.23  Preparation of 6-(N-methylanilino)-2-n-octylaminopyrimidin-4(3H)-one (7b). A mixture of 
6-(N-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1a, 1.24 g, 5.0 mmol) and n-octylamine (2.58 g, 0.02 mol) 
was heated at 160 °C for 10 h. After cooling, the resulting mixture was triturated with water and acidified with 
acetic acid to remove the excess n-octylamine as salt. The product was extracted from the mixture with 
dichloromethane (3 x 50 mL) and the extract was washed with saturated brine (2 x 20 mL). The combined organic 
extracts were dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced 
pressure to afford the product 7b as orange oil. The product which was dried under vacuum was used for the next 
step without further purification. 
Yield, (1.41 g, 86%); oily compound; UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 230 (4.56), 259sh (4.28), 282 
(4.29); IR (νmax/cm-1): 3278, 3156 (NH), 1640 (C=O); 1H NMR (CDCl3): δ 0.84–0.92 (3H, m, 2-N-(CH2)7-CH3), 
1.22–1.33 (10H, m, 2-N-(CH2)2-(CH2)5-CH3), 1.38–1.59 (2H, m,2-N-CH2-CH2-(CH2)5-CH3), 3.27 (2H, q, J = 7.2, 
Hz, 2-N-CH2-(CH2)6-CH3), 3.41 (3H, s, 6-NMe), 4.66 (1H, s, 5-H), 5.82 (1H, br s, 2-NH, exchangeable with D2O), 
7.19–7.28 (3H, m, Ph-o,pH), 7.34–7.42 (2H, m, Ph-mH), 11.57 (1H, br s, 3-NH, exchangeable with D2O). 
 
4.1.24.  General procedure for the preparation of 2-alkylamino-2-deoxo-10-methyl-5-deazaflavins {2-alkyl- 
amino-10-methylpyrimido[4,5-b]quinolin-4(10H)-ones} (8a,b). A mixture of 2-alkylamino-6-(N-methylanilino)- 
pyrimidin-4(3H)-ones (7, 5.0 mmol) and phosphoryl chloride (3.83 g, 25 mmol) in anhydrous DMF (5 mL) was 
heated under stirring at 90 °C for 3 h. Then, the reaction mixture was poured onto ice and treated with aqueous 
ammonia (pH 8). The separated yellow crystals were filtered off, washed with water, dried and recrystallized from 
an appropriate solvent to afford the products as yellow needles in 60–82% yields. 
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4.1.25.  10-Methyl-2-methylaminopyrimido[4,5-b]quinolin-4-(10H)-one (8a). Yield, (0.99 g, 82%); mp 
259–251 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (5.07), 269 (4.20), 275sh 
(4.16), 321 (3.67), 410 (3.66); IR (νmax/cm-1): 3290 (NH), 1705 (C=O); 1H NMR (CDCl3): δ 3.34 (3H, s, 
2-NMe),4.10 (3H, s, 10-Me), 7.46–7.58 (1H, m, 7-H), 7.67 (1H, br s, 2-NH, exchangeable with D2O), 7.82–7.98 (2H, 
br m, 8 and 9-H), 8.11 (1H, br d, J6,7 = 7.8 Hz, 6-H), 8.82 (1H, s, 5-H); Anal. calcd for C13H12N4O· 0.7H2O: C, 
61.75; H, 5.34; N, 22.16. Found: C, 62.04; H, 5.74; N, 22.0.   
 
4.1.26.  10-Methyl-2-n-octylaminopyrimido[4,5-b]quinolin-4-(10H)-one (8b). 18Yield, (1.02 g, 60%); mp 
187–189 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.45), 269 (4.54), 275sh 
(4.47), 320 (3.98), 406 (4.05); IR (νmax/cm-1): 3220 (NH), 1720 (C=O); 1H NMR [(CD3)2SO], at 100 °C: δ 0.86 (3H, 
t, J = 7.2 Hz, 2-N(CH2)7-CH3), 1.20–1.42 (10H, m, 2-N(CH2)2-(CH2)5-CH3), 1.60 (2H, quint, J = 7.2 Hz, 
2-NCH2-CH2-(CH2)5-CH3), 3.35–3.51 (2H, m, 2-NCH2-(CH2)6-CH3), 4.07 (3H, s, 10-Me), 7.17 (1H, br s, 2-NH, 
exchangeable with D2O), 7.42–7.53 (1H, m, 7-H), 7.75–7.93 (2H, m, 8 and 9-H), 8.07 (1H, d, J = 8.1 Hz, 6-H), 8.77 
(1H, s, 5-H); Anal. calcd for C20H26N4O· 0.1H2O: C, 70.60; H, 7.76; N, 16.47. Found: C, 70.30; H, 7.59; N, 16.14.  
 
4.1.27.  General procedure for the preparation of 2-alkylamino-2-deoxo-10-methylflavin-5-oxides 
{2-alkylamino-10-methyl-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxides} (9a,b). To a stirring solution of 
2-alkylamino-6-(N-methylanilino)pyrimidin-4(3H)-ones (7, 5.0 mmol) in acetic acid (5–15 mL) at 10–15 °C was 
added sodium nitrite (0.01–0.02 mol) by portions, and the mixture was stirred at room temperature for 2–3 h. The 
solid deposited was collected by suction filtration and washed well with water. The filtrate was concentrated in 
vacuo and diluted with excess water to afford the second crop. The collected solids were washed with diluted 
ammonia solution, dried and crystallized from an appropriate solvent to afford the corresponding products as orange 
needles in 76–88% yields. 
 
4.1.28.  10-Methyl-2-methylamino-4-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (9a). Yield, (1.13 g, 88%); 
mp >300 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 216 (4.27), 247sh (4.34), 274 
(4.48), 348 (3.99), 455 (4.05); IR (νmax/cm-1): 3290 (NH), 1670 (C=O); 1H NMR [(CD3)2SO], at 85 °C : δ 2.89 (3H, 
s, 2-NMe), 3.93 (3H, s, 10-Me), 7.31 (1H, br s, 2-NH, exchangeable with D2O), 7.43–7.62 (1H, m, 7-H), 7.78–8.0 
(2H, m, 8 and 9-H), 8.34 (1H, d, J = 8.1 Hz, 6-H); Anal. calcd for C12H11N5O2·0.2 H2O: C, 55.25; H, 4.41; N, 26.85. 
Found: C, 55.09; H, 4.54; N, 26.85. 
 
4.1.29.  10-Methyl-2-n-octylamino-oxo-4,10-dihydrobenzo[g]pteridine-5-oxide (9b). Yield, (1.35 g, 76%); mp 
172–174 °C (from EtOAc); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 216 (4.40), 246sh (4.29), 273 (4.47), 347 
(3.95), 444 (4.05); IR (νmax/cm-1): 3270 (NH), 1655 (C=O); 1H NMR [(CD3)2SO], at 100 °C : δ 0.89 (3H, t, J = 6.6 
Hz, 2-N(CH2)7-CH3), 1.22–1.45 (10H, m, 2-N(CH2)2-(CH2)5-CH3), 1.61 (2H, quint, J = 6.6 Hz, 2-NCH2-CH2 
-(CH2)5-CH3), 3.30–3.51 (2H, m, 2-NCH2-(CH2)6-CH3), 3.96 (3H, s, 10-Me), 7.32 (1H, br s, 2-NH, exchangeable 
with D2O), 7.43–7.65 (1H, m, 7-H), 7.75–8.0 (2H, m, 8 and 9-H), 8.36 (1H, d, J = 8.4 Hz, 6-H); Anal. calcd for 
C19H25N5O2: C, 64.20; H, 7.09; N, 19.70. Found: C, 64.14; H, 6.83; N, 19.48. 
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4.1.30. General procedure for the preparation of 6-(N-anilino)-4-oxo-2-thioxo-1,2,3,4-tetradropyrimidines 
(10a–e). A mixture of 6-amino-2-thiouracil (7.10 g, 0.05 mol), an appropriate aniline (0.1 mol) together with 
anilinium chloride (0.075–0.10 mol) was heated at 170 °C for 4–12 h. The cooled mixture was diluted with 65% 
ethanol (200 mL) to afford the solid product, which was collected by filtration, dissolved in hot ca. 5% NaOH 
solution, and reprecipitated by neutralization with 10% HCl to get more pure product. The solid deposited was 
collected by suction filtration, washed with water, dried and crystallized from a mixture of DMF and H2O to afford 
the corresponding products as colorless needles in 67–83% yields. 
 
4.1.31.  6-Anilino-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (10a). Yield, (9.10 g, 83%); mp 296–298 °C 
(decomp., from DMF-H2O); (lit.,23,24 287–288 and 281–283 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 205 
(4.47), 277 (4.57); IR (νmax/cm-1): 3335, 3220, 3105 (NH), 1670 (C=O); 1H NMR (CDCl3): δ 5.19 (1H, s, 5-H), 
7.15–7.23 (3H, m, Ph-o,pH), 7.34–7.40 (2H, m, Ph-mH), 7.78 (1H, s, 6-NH ), 11.28 (1H, br s, 1-NH), 11.41 (1H, br 
s, 3-NH); Anal. calcd for C10H9N3OS· 0.1H2O: C, 54.33; H, 4.19; N, 19.01. Found: C, 54.27; H, 4.20; N, 18.80. 
 
4.1.32.  6-(4-Methylanilino)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (10b). Yield, (7.82 g, 67%); mp 
293–295 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 205 (4.41), 255 (4.24); IR 
(νmax/cm-1): 3330, 3210, 3120 (NH), 1655 (C=O); 1H NMR [(CD3)2SO]: δ 2.30 (3H, s, Me), 4.85 (1H, s, 5-H), 7.11 
(2H, br d, JAB = 7.8 Hz, Ar-oH), 7.21 (2H, br d, JAB = 7.8 Hz, Ar-mH), 8.06 (1H, s, 6-NH ), 11.49 (1H, br s, 1-NH), 
11.86 (1H, br s, 3-NH); Anal. calcd for C11H11N3OS: C, 56.63; H, 4.75; N, 18.01. Found: C, 56.32; H, 5.08; N, 
17.65. 
 
4.1.33.  6-(2,4-Dimethylanilino)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (10c). Yield, (9.77 g, 79%); mp 
293–295 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 204 (4.45), 275 (4.41); IR 
(νmax/cm-1): 3350, 3190, 3095 (NH), 1650 (C=O); 1H NMR [(CD3)2SO]: δ 2.27 (6H, s, 2' and 4'-CH3 ),  5.50 (1H, s, 
5-H), 6.69 (1H, s, 6-NH), 7.09 (1H, s, Ar-3'-H), 7.50–7.57 (1H, m, Ar-5'-H), 8.14 (1H, d, J5',6' = 8.1 Hz, Ar-6'-H), 
9.04 (1H, s, 1-NH), 11.98 (1H, br s, 3-NH); Anal. calcd for C12H13N3OS: C, 58.28; H, 5.30; N, 16.99. Found: C, 
58.05; H, 5.39; N, 17.14. 
 
4.1.34.  6-(4-Methoxyanilino)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (10d). Yield, (9.60 g, 77%); mp 
284–286 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 204 (4.36), 278 (4.35); IR 
(νmax/cm-1): 3340, 3240, 3100 (NH), 1665 (C=O); 1H NMR [(CD3)2SO]: δ 3.76 (3H, s, OMe), 4.66 (1H, s, 5-H), 
6.98 (2H, dd, J2’,3’ = J5’,6’ = 8.7 Hz, J2',6' = 2.1 Hz, Ar-oH), 7.17 (2H, dd, J2’,3’ = J5’,6’ = 8.7 Hz, J3',5', = 2.1 Hz, Ar-mH), 
7.92 (1H, s, 6-NH), 11.53 (1H, br s, 1-NH), 11.83 (1H, br s, 3-NH); Anal. calcd for C11H11N3O2S: C, 53.00; H, 4.45; 
N, 16.86. Found: C, 52.87; H, 4.52; N, 16.70. 
 
4.1.35.  6-(4-Hydroxyanilino)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (10e). Yield, (8.35 g, 71%); mp 
>300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 208 (4.43), 279 (4.47); IR 
(νmax/cm-1): 3330 (OH), 3285 , 3205, 3095 (NH), 1685 (C=O); 1H NMR [(CD3)2SO]: δ 4.60 (1H, s, 5-H), 6.79 (2H, 
dd, J2’,3’ = J5’,6’ = 8.7 Hz, J2',6' = 2.1 Hz, Ar-oH), 7.05 (2H, dd, J2',3' = J5',6' = 8.7 Hz, J3',5' = 2.1 Hz , Ar-mH), 7.81 (1H, 
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s, 6-NH ), 9.55 (1H, s, OH), 11.51 (1H, br s, 1-NH), 11.81 (1H, br s, 3-NH); Anal. calcd for C10H9N3O2S: C, 51.05; 
H, 3.86; N, 17.86. Found: C, 50.79; H, 4.19; N, 17.63. 
 
4.1.36. General procedure for the preparation of 6-anilino-2-methylthio-4-oxo-3,4-dihyropyrimidines (11a–e). 
To a solution of 6-anilino-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidines (10, 0.01 mol), in 2N KOH (250 mL) at 
0–5 °C was added methyl iodide (2.84 g, 0.02 mol) and the solution was shaken vigorously under chilling for 30 
min. The solid precipitated was collected by filtration and the filtrate was neutralized with 10% HCl to get the 
second crop. The collected solid products were dissolved in hot ca. 5% NaOH solution and reprecipitated by 
neutralization with 10% HCl to get the more pure products. The solid products were collected by suction filtration 
and washed with water, dried, crystallized from an appropriate solvent to afford the corresponding silver colored 
crystals in 77–98% yields.  
 
4.1.37.  6-Anilino-2-methylthio-4-oxo-3,4-dihydropyrimidine (11a). Yield, (2.10 g, 90%); mp 294–295 °C 
(decomp., from MeOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 204 (4.46), 258 (4.41), 297 (4.16); IR 
(νmax/cm-1): 3250, 3140 (NH), 1640 (C=O); 1H NMR [(CD3)2SO]: δ 2.47 (3H, s, 2-SMe), 5.32 (1H, s, 5-H), 6.98 
(1H, br t, J = 7.5 Hz, Ph-pH), 7.29 (2H, br t, J = 7.5 Hz, Ph-mH), 7.42 (2H, br d, J = 7.5 Hz, Ph-oH), 9.06 (1H, s, 
6-NH), 11.84 (1H, br s, 3-NH); Anal. calcd for C11H11N3OS: C, 56.63; H, 4.75; N, 18.01. Found: C, 56.32; H, 4.78; 
N, 17.66.  
 
4.1.38.  6-(4-Methylanilino)-2-methylthio-4-oxo-3,4-dihydropyrimidine (11b). Yield, (1.90 g, 77%); mp 
252–254 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 204 (4.39), 258 (4.38), 305 
(4.09); IR (νmax/cm-1): 3300, 3160 (NH), 1640 (C=O); 1H NMR (CDCl3): δ 2.34 (3H, s, Ar-pMe), 2.54 (3H, s, 
2-SMe), 5.51 (1H, s, 5-H), 6.47 (1H, s, 6-NH), 7.12 (2H, d , JAB = 8.7 Hz , Ar-oH), 7.16 (2H, d, JAB = 8.7 Hz , 
Ar-mH), 12.76 (1H, br s, 3-NH); Anal. calcd for C12H13N3OS: C, 58.28; H, 5.30; N, 16.99. Found: C, 58.06; H, 
5.41; N, 16.71. 
 
4.1.39.  6-(2,4-Dimethylanilino)-2-methylthio-4-oxo-3,4-dihydropyrimidine (11c). Yield, (2.56 g, 98%); mp 
258–260 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 208 (4.52), 245 (4.50), 286 
(4.10); IR (νmax/cm-1): 3390, 3140 (NH), 1640 (C=O); 1H NMR (CDCl3): δ 2.22 (3H, s, 2'-Me), 2.32 (3H, s, 4'-Me), 
2.53 (3H, s, 2-SMe), 5.04 (1H, s, 5-H), 6.16 (1H, s, 6-NH), 7.00 (1H, d, J5',6' = 7.8 Hz, Ar-5'-H), 7.06 (1H, s, 
Ar-3'-H), 7.12 (1H, d, J5',6' = 7.8 Hz, Ar-6'-H ), 12.26 (1H, br s, 3-NH); Anal. calcd for C13H15N3OS: C, 59.74; H, 
5.79; N, 16.08. Found: C, 59.44; H, 5.85; N, 15.89. 
 
4.1.40.  6-(4-Methoxyanilino)-2-methylthio-4-oxo-3,4-dihydropyrimidine (11d). Yield, (2.24 g, 85%); mp 
229–231 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 209 (4.45), 257 (4.48), 300 
(4.21); IR (νmax/cm-1): 3310, 3160 (NH), 1640 (C=O); 1H NMR (CDCl3): δ 2.53 (3H, s, 2-SMe), 3.81 (3H, s, 
4'-OMe), 5.32 (1H, s, 5-H), 6.33 (1H, s, 6-NH), 6.88 (2H, d, JA,B = 9.0 Hz, Ar-oH), 7.15 (2H, d, JA,B = 9.0 Hz, 
Ar-mH), 11.98 (1H, br s, 3-NH); Anal. calcd for C12H13N3O2S: C, 54.74; H, 4.98; N, 15.96. Found: C, 54.78; H, 
5.02; N, 15.79. 
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4.1.41.  6-(4-Hydroxyanilino)-2-methylthio-4-oxo-3,4-dihydropyrimidine (11e). Yield, (2.34 g, 94%); mp 
293–295 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 209 (4.54), 252 (4.49), 296 
(4.20); IR (νmax/cm-1): 3400 (OH), 3380, 3210 (NH), 1640 (C=O); 1H NMR [(CD3)2SO]: δ 2.45 (3H, s, 2-SMe), 
5.06 (1H, s, 5-H), 6.72 (2H, d, JA,B = 8.7 Hz, Ar-oH), 7.13 (2H, d, JA,B = 8.7 Hz, Ar-mH), 8.75 (1H, s, 6-NH ), 9.23 
(1H, s, OH), 11.86 (1H, br s, 3-NH); Anal. calcd for C11H11N3O2S· 0.1H2O: C, 52.62; H, 4.50; N,16.74. Found: C, 
52.53; H, 4.68; N, 16.35.  
 
4.1.42.  General procedure for the preparation of 2-deoxo-2-methylthio-5-deazaalloxazines {2-methylthio- 
pyrimido[4,5-b]quinolin-4(3H)-ones} (12a, b). A mixture of 6-anilino-2-methylthio-4-oxo-3,4-dihydropyrimidines 
(11, 0.01 mol) and phosphoryl chloride (7.7 g, 0.05 mol) in anhydrous DMF (10 mL) was heated under stirring at 
90 °C for 1 h. Then, the reaction mixture was poured onto ice and neutralized with aqueous ammonia (pH 7). The 
yellow crystals separated were filtered off, washed with water, dried and recrystallized from an appropriate solvent 
to afford the corresponding products as pale yellow needles in 63–72% yields. 
 
4.1.43.  2-Methylthiopyrimido[4,5-b]quinolin-4(3H)-one (12a). Yield, (1.75 g, 72%), mp 292–294 °C (decomp., 
from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 (4.49), 239sh (4.35), 273sh (4.54), 283 (4.64), 
313sh (3.78), 366 (3.86), 381 (3.75); IR (νmax/cm-1): 3160 (NH), 1680 (C=O); 1H NMR (CDCl3): δ 2.83 (3H, s, 
2-SMe), 7.58 (1H, br t, J6,7 = J7,8 = 7.5 Hz, 7-H), 7.86 (1H, br t, J7,8 = J8,9 = 7.5 Hz, 8-H), 7.99 (1H, br d, J8,9 = 7.5 Hz, 
9-H), 8.22 (1H, br d, J6,7 = 7.5 Hz, 6-H), 9.16 (1H, s, 5-H), 9.43 (1H, br s, 3-NH, exchangeable with D2O); Anal. 
calcd for C12H9N3OS· 0.1 H2O: C, 58.81; H, 3.78; N, 17.15. Found: C, 58.79; H, 4.08; N, 16.76. 
 
4.1.44.  7,9-Dimethyl-2-methylthiopyrimido[4,5-b]quinolin-4(3H)-one (12b). Yield, (1.71 g, 63%), mp >300 °C 
(decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 230 (4.33), 244sh (4.38), 278sh (4.55), 287 
(4.62), 320sh (3.91), 369 (3.80), 393 (3.66); IR (νmax/cm-1): 3160 (NH), 1660 (C=O); 1H NMR (CDCl3): δ 2.47 (3H, 
s, 7-Me), 2.66 (3H, s, 9-Me), 2.70 (3H, s, 2-SMe), 7.61 (1H, s, 8-H), 7.77 (1H, s, 6-H), 8.98 (1H, s, 5-H), 12.69 (1H, 
br s, 3-NH, exchangeable with D2O); Anal. calcd for C14H13N3OS· 0.4 H2O: C, 60.37; H, 4.99; N, 15.09. Found: C, 
60.15; H, 5.04; N, 14.88.  
 
4.1.45.  General procedure for the preparation of 2-deoxo-2-methylthioalloxazine-5-oxides {2-methylthio-4- 
oxo-3,4-dihydrobenzo[g]pteridine-5-oxides} (13a-e). To a stirring solution of 6-anilino-2-methylthio-4-oxo-3,4- 
dihydropyrimidines (11, 0.01 mol) in acetic acid (5–15 mL) at 10–15 °C was added sodium nitrite (0.02–0.04 mol) 
by portions, and the mixture was stirred at room temperature with occasional warming in water bath to enhance the 
cyclization for 1–2 h. The solid deposited was collected by suction filtration and washed with water. The filtrate was 
concentrated in vacuo and the residue was diluted with excess water or neutralized with aqueous ammonia (pH 7) to 
afford the second crop. The solid dried was crystallized from a mixture of DMF and water to afford the 
corresponding products as yellow or orange needles in 66–89% yields. 
 
4.1.46.  2-Methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13a). Yield, (2.32 g, 89%); mp >300 °C 
(decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 244 (4.30), 270 (4.45), 292 (4.42), 355 
(3.87), 446 (3.81); IR (νmax/cm-1): 3200 (NH), 1690 (C=O); 1H NMR [(CD3)2SO]: δ 2.44 (3H, s, 2-SMe), 7.55 (1H, 
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d t, J6,7 = J7,8 = 8.7 Hz, J7,9 = 1.5 Hz, 7-H), 7.76–7.87 (2H, m, 6 and 8-H), 8.32 (1H, dd, J6,7 = 8.7, J6,8 = 0.9 Hz, 6-H), 
12.69 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C11H8N4O2S: C, 50.76; H, 3.10; N, 21.53. Found: C, 
50.58; H, 3.39; N, 21.30. 
 
4.1.47.  7,9-Dimethyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13b). Yield, (2.36 g, 82%); 
mp >300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 247 (4.42), 275 (4.79), 298 
(4.71), 361 (3.92), 453 (3.99); IR (νmax/cm-1): 3180 (NH), 1680 (C=O); 1H NMR [(CD3)2SO]: δ 2.49 (3H, s, 7-Me), 
2.61 (3H, s, 2-SMe), 2.62 (3H, s, 9-Me), 7.61 (1H, br s, 8-H), 7.98 (1H, br s, 6-H), 12.76 (1H, br s, 3-NH, 
exchangeable with D2O); Anal. calcd C13H12N4O2S: C, 54.15; H, 4.19; N, 19.43. Found: C, 54.25; H, 4.53; N, 
19.37. 
 
4.1.48.  7-Methoxy-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13c). Yield, (2.38 g, 82%); mp 
>300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 242 (4.19), 275sh (4.61), 285 
(4.72), 352 (3.83), 457 (3.94); IR (νmax/cm-1): 3175 (NH), 1695 (C=O); 1H NMR [(CD3)2SO]: δ 2.59 (3H, s, 2-SMe), 
3.97 (3H, s, 7-OMe), 7.60 (1H, dd, J8,9 = 9.3 Hz, J6,8 = 2.7 Hz , 8-H), 7.67 (1H, d, J6,8 = 2.7 Hz , 6-H), 7.93 (1H, d, 
J8,9 = 9.3 Hz, 9-H), 12.78 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C12H10N4O3S: C, 49.65; H, 
3.47; N, 19.30. Found: C, 49.79; H, 3.76; N, 19.33. 
 
4.1.49.  7-Methyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13d). Yield, (1.81 g, 66%); mp 
>300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 241 (4.10), 274 (4.56), 295 
(4.50), 351 (3.85), 443 (3.85); IR (νmax/cm-1): 3175 (NH), 1695 (C=O); 1H NMR [(CD3)2SO]: δ 2.55 (3H, s, 7-Me), 
2.59 (3H, s, 2-SMe), 7.78 (1H, d, J8,9 = 8.4 Hz, 9-H), 7.90 (1H, br d, J8,9 = 8.4 Hz, 8-H), 8.16 (1H, br s, 6-H), 12.79 
(1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C12H10N4O2S: C, 52.54; H, 3.67; N, 20.43. Found: C, 
52.58; H, 4.06; N, 20.19. 
 
4.1.50.  7-Hydroxy-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13e). Yield, (1.81 g, 66%); mp 
>300 °C (decomp., from DMF-H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 (4.35), 280 (4.28), 422 
(3.70); IR (νmax/cm-1): 3260 (OH), 3100 (NH), 1700 (C=O); 1H NMR [(CD3)2SO]: δ 2.61 (3H, s, 2-SMe), 7.39 (1H, 
d, J8,9 = 9.0 Hz, 9-H), 8.24 (1H, dd, J8,9 = 9.0 Hz, J6,8 = 2.7 Hz , 8-H), 8.73 (1H, d, J6,8 = 2.7 Hz, 6-H), 11.67 (1H, s, 
7-OH), 13.19 (1H, br s, 3-NH exchangeable with D2O); Anal. calcd for C11H8N4O3S· 0.6H2O: C, 46.02; H, 3.23; N, 
19.52. Found: C, 45.61; H, 3.41; N, 19.49. 
 
4.1.51.  General procedure for the preparation of 2-alkylaminopyrimido[4,5-b]quinolin-4-(3H)-one (14a,b). 
A mixture of 2-methylthiopyrimido[4,5-b]quinolin-4(3H)-ones (12a, 5.0 mmol) and appropriate amine (0.035–0.05 
mol) in DMF (30 mL) for compound 14a or in n-butanol (20 mL) for compound 14b was refluxed with stirring for 
15–24 hours. After the resulting clear yellow solution was kept in refrigerator overnight, the yellow crystals 
precipitated were collected by filtration to get the first crop. The filtrate was concentrated in vacuo to remove the 
excess amine and the residue was treated with water to get the second crop free from amine. The collected solids 
were dried and recrystallized from ethanol to give the pure products as yellow needles in 82–84% yields. 
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4.1.52.  2-Morpholinopyrimido[4,5-b]quinolin-4-(3H)-one (14a). Yield, (1.19 g, 84%); mp 288–291 °C 
(decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (4.53), 263 (4.45), 280 (4.57), 321sh 
(3.88), 408 (3.97), 434 (3.39); IR (νmax/cm-1): 3260 (NH), 1660 (C=O);1H NMR (CDCl3): δ 3.82–3.90 (4H, m, 2' 
and 6'-CH2), 3.90–4.01 (4H, m, 3' and 5'-CH2), 7.47 (1H, t, J6,7 = J7,8 = 7.2 Hz, 7-H), 7.79 (1H, t, J7,8 = J8,9 = 7.2 Hz, 
8-H), 7.92 (1H, d, J8,9 = 7.2 Hz, 9-H), 7.98–8.12 (1H, m, 6-H), 8.96 (1H, s, 5-H), 10.65 (1H, br s, 3-NH, 
exchangeable with D2O); Anal. calcd for C15H14N4O2· 0.2H2O: C, 63.02; H, 5.08; N, 19.60. Found: C, 62.76; H, 
5.19; N, 19.36. 
 
4.1.53.  2-[N-(2-Hydroxyethyl)-N-methylamino]-7,9-dimethylpyrimido[4,5-b]quinolin-4-(3H)-one (14b). 
Yield, (1.22 g, 82%); mp 273–275 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 246 
(4.42), 266 (4.64), 287 (4.36), 322 (3.96), 366 (3.65);  IR (νmax/cm-1): 3260 (NH), 1660 (C=O); 1H NMR (CDCl3): 
δ 2.48 (3H, s, 7-Me), 2.74 (3H, s, 9-Me), 3.35 (3H, s, 2-NMe), 3.73 (2H, br s, 2-N-CH2-CH2-OH), 3.88 (2H, br s, 
2-N-CH2-CH2-OH), 5.50 (1H, br s, 2-N-CH2-CH2-OH, exchangeable with D2O), 7.50 (1H, s, 8-H), 7.52 (1H, s, 
6-H), 8.82 (1H, s, 5-H), 11.09 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C16H18N4O2· 0.2EtOH: C, 
64.05; H, 6.29; N, 18.22. Found: C, 63.74; H, 6.29; N, 17.83.  
 
4.1.54.  Preparation of 7-methoxy-2-morpholino-4-oxo-3,4-dihydrobenzo[g]pteridine (15a). A mixture of 
7-methoxy-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13c, 2.90 g, 0.01 mol) and morpholine (8.71 
g, 0.10 mol) in DMF (30 mL) was refluxed with stirring for 6 h. After the resulting solution was kept in refrigerator 
overnight, the yellow crystals precipitated were collected by filtration to get the product which was washed with 
ethyl acetate, dried and recrystallized from DMF to give the yellow pure product 15a. 
Yield, (2.10 g, 67%); mp >300 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 224 (4.14), 
275 (4.47), 332 (3.51), 446 (3.85); IR (νmax/cm-1): 3135 (NH), 1698 (C=O); 1H NMR (CDCl3): δ 3.92 (4H, br m, 2' 
and 6'-CH2), 3.93 (4H, br m, 3' and 5'-CH2), 3.98 (3H, s, 7-OMe), 7.45–7.57 (2H, m, 6 and 8-H), 7.96 (1H, d, J8,9 = 
9.0 Hz, 9-H), 10.62 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 
22.35. Found: C, 57.15; H, 5.02; N, 22.44 
 
4.1.55.  Preparation of 2-dimethylamino-4-oxo-3,4-dihydrobenzo[g]pteridine (15b). A mixture of 
2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (13a, 2.6 g, 0.01 mol) and 50% aqueous dimethylamine 
(50 mL) of was heated in steel sealed tube at 135 °C (10 kg/cm2 pressure) for 8 h. After the reaction was complete, 
the resulting clear yellow solution was concentrated in vacuo and the yellow solid residue was washed with water, 
dried and crystallized from ethanol to afford the pure product as yellow crystals. 
Yield, (2.08 g, 86%); mp >300 °C (decomp., from H2O); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.38), 
269 (4.31), 287 (4.29), 334 (3.62), 376sh (3.58), 399 (3.68), 430 (3.78); IR (νmax/cm-1): 1700 (C=O); 1H NMR 
(CDCl3): δ 3.39 (6H, s, 2-N (CH3)2 ), 7.64 (1H, dt, J6,7 = J7,8 = 8.4 Hz, J7, 9 = 1.5 Hz, 7-H), 7.79 (1H, dt, J7,8 = J8,9 = 
8.4 Hz, J6,8 = 1.5 Hz, 8-H), 8.02 (1H, d, J8,9 = 8.4 Hz, 9-H), 8.21 (1H, d, J6,7 = 8.4 Hz, 6-H); Anal. calcd for 
C12H11N5O· 0.1H2O: C, 59.30; H, 4.64; N, 28.81. Found: C, 59.23; H, 4.72; N, 28.41. 
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4.1.56.  General procedure for the preparation of 3-alkyl-2-deoxo-2-methylthioalloxazine-5-oxides { 3- 
alkyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxides} (16a–e).  A mixture of 2-methylthio-4-oxo- 
3,4-dihydrobenzo[g]pteridine-5-oxides (13, 5.0 mmol), alkyl iodide or alkyl bromide (0.015–0.025 mol), and 
anhydrous potassium carbonate (2.76 g, 0.02 mol) in DMF (30 mL) was stirred at room temperature for 3–10 h. 
After the reaction was complete, the insoluble potassium carbonate was filtered off and washed with CH2Cl2. The 
combined solution of the filtrate and washing solution of CH2Cl2 was concentrated in vacuo. The residue was 
dissolved in water and extracted with CH2Cl2 (3 x 50 mL), dried over anhydrous magnesium sulfate and filtered. 
Then, the solvent was removed in vacuo to afford the solid, which was collected by filtration, dried, and crystallized 
from ethanol to afford the corresponding products as yellow crystals in 71–82% yields. 
 
4.1.57.  3-Methyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (16a). Yield, (1.13 g, 82%); mp 
231–233 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 (3.72), 272 (4.32), 299 (4.40), 
337sh (3.77), 422 (3.64), 445sh (3.48); IR (νmax/cm-1): 1700 (C=O); 1H NMR (CDCl3): δ 2.79 (3H, s, 2-SMe), 3.64 
(3H, s, 3-NMe), 7.66 (1H, d t, J6,7 = 9.0 Hz, J7,8 = 8.7 Hz, J7,9 = 1.5 Hz, 7-H), 7.85 (1H, d t, J7,8 = J8,9 = 8.7 Hz, J6,8 = 
1.5 Hz, 8-H), 8.13 (1H, br d, J8,9 = 8.7, 9-H), 8.56 (1H, br d, J6,7 = 9.0, 6-H); Anal. calcd for C12H10N4O2S: C, 52.54; 
H, 3.67; N, 20.43. Found: C, 52.67; H, 3.94; N, 20.74. 
 
4.1.58.  3,7,9-Trimethyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (16b). Yield, (1.21 g, 
80%); mp 264–266 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (3.79), 280 (4.52), 
304 (4.55), 344sh (3.72), 431 (3.72), 458sh (3.50); IR (νmax/cm-1): 1698 (C=O); 1H NMR (CDCl3): δ 2.54 (3H, s, 
7-Me), 2.79 (3H, s, 2-SMe), 2.81 (3H, s, 9-Me), 3.63 (3H, s, 3-NMe), 7.53 (1H, br s, 8-H), 8.20 (1H, br s, 6-H); 
Anal. calcd for C14H14N4O2S: C, 55.61; H, 4.67; N, 18.53. Found: C, 55.20; H, 4.92; N, 18.20. 
 
4.1.59.  3-Ethyl-7,9-dimethyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (16c). Yield, (1.12 g, 
71%); mp 210–212 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 227 (3.63), 280 (4.49), 
304 (4.56), 343sh (3.77), 432 (3.77), 457sh (3.56); IR (νmax/cm-1): 1698 (C=O); 1H NMR (CDCl3): δ 1.41 (3H, t, J = 
7.2 Hz, 3-NCH2-CH3), 2.54 (3H, s, 7-Me), 2.79  (3H, s, 2-SMe), 2.80 (3H, s, 9-Me), 4.22 (2H, q, J = 7.2 Hz, 
3-NCH2-CH3), 7.53 (1H, br s, 8-H), 8.20 (1H, br s, 6-H); Anal. calcd for C15H16N4O2S: C, 56.94; H, 5.10; N, 17.71. 
Found: C, 56.75; H, 5.25; N, 17.38. 
 
4.1.60.  3-(Ethoxycarbonylmethyl)-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridin-5-oxide (16d). Yield, 
(1.28 g, 74%); mp 212–214 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 (4.31), 
272 (4.51), 299 (4.63), 336sh (3.95), 415 (3.79), 443sh (3.60); IR (νmax/cm-1): 1740, 1705 (C=O); 1H NMR (CDCl3): 
δ 1.31 (3H, t, J = 7.2 Hz, 3-CH2COOCH2CH3), 2.81 (3H, s, 2-SMe), 4.28 (2H, q, J = 7.2 Hz, 3-NCH2COOCH2CH3), 
4.91 (2H, s, 3-NCH2COOCH2CH3), 7.68 (1H, d t, J6,7 = J7,8 = 8.7 Hz, J7,9 = 1.8 Hz, 7-H), 7.88 (1H, d t, J7,8 = J8,9 = 
8.7 Hz, J6,8 = 1.8 Hz, 8-H), 8.14 (1H, dd, J8,9 = 8.7 Hz, J7,9 = 1.8 Hz, 9-H), 8.55 (1H, dd, J6,7 = 8.7 Hz, J6,8 = 1.8 Hz, 
6-H); Anal. calcd for C15H14N4O4S: C, 52.02; H, 4.07; N, 16.18. Found: C, 52.24; H, 4.38; N, 15.85. 
 
4.1.61.  3,7-Dimethyl-2-methylthio-4-oxo-3,4-dihydrobenzo[g]pteridine-5-oxide (16e). Yield, (1.14 g, 79%); 
mp 211–213 °C (decomp., from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 229 (3.42), 278 (4.10), 299 
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(4.07), 338sh (3.48), 427 (3.37), 449sh (3.21); IR (νmax/cm-1): 1700 (C=O); 1H NMR (CDCl3): δ 2.60 (3H, s, 7-Me), 
2.78 (3H, s, 2-SMe), 3.64 (3H, s, 3-NMe), 7.68 (1H, dd, J8,9 = 8.7 Hz, J6,8 = 2.1 Hz, 8-H), 8.02 (1H, d, J8,9 = 8.7 Hz, 
Hz, 9-H), 8.34 (1H, br s, 6-H); Anal. calcd for C13H12N4O2S: C, 54.15; H, 4.19; N, 19.43. Found: C, 54.48; H, 4.34; 
N, 19.17. 
 
4.2. Growth inhibitory activities of against human tumor cell lines 
The procedure was carried out using the modified 3-(3,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) colorimetric assay25 to determine the inhibitory effects of test compounds, namely, 10-alkyl-2-deoxo-2- 
methylthioflavin-5-oxides (2a–i), 10-alkyl-2-alkylamino-2-deoxoflavin-5-oxides (4a–e), 10-alkylflavins (5a,b),  
7-methoxy-10-methylflavin-5-oxide (6), 2-alkylamino-2-deoxo-10-methyl-5-deazaflavins (8a,b), 
2-deoxo-10-methyl-2-methylaminoflavin-5-oxide (9a), 2-deoxo-2-methylthio-5-deazaalloxazine (12a), 
2-deoxo-2-methylthioalloxazine-5-oxides (13a–d), 2-alkylamino-2-deoxoalloxazines (15a,b), and 
3-alkyl-2-deoxo-2-methylthioalloxazine-5-oxides (16a–e), on cell growth in vitro as mentioned in detail in our 
previous paper.6 Two human tumor cell lines of CCRF-HSB-2 (human T-cell acute lymphoblastoid leukemia) and 
KB (human oral epidermoid carcinoma) were used in this study. AraC was used as a positive control, where the IC50 
was determined from the dose–response curve. 
 
4.3.  Molecular docking study 
The automated docking studies were carried out using AutoDock version 3.0.5.26 First, AutoGrid component of the 
program pre-calculates a three-dimensional grid of interaction energies based on the macromolecular target using the 
AMBER force field. The cubic grid box of 80 Å size (x, y, z) with a spacing of 0.375 Å and grid maps were created 
representing the catalytic active target site region where the native ligand were embedded. Then automated docking 
studies were carried out to evaluate the binding free energy of the inhibitors within the macromolecules. The GA-LS 
search algorithm (Genetic algorithm with local search) was chosen to search for the best conformers. The parameters 
were set using the software ADT (Autodock Tool Kit) on PC which is associated with Autodock 3.0.5.  For all 
docking parameters, default values were used with 10 independent docking runs for each docking case. The 
AutoDock performs the task of the docking, where the ligand moves randomly in any one of six degrees of freedom, 
and the energy of the new ligand ‘‘state’’ is calculated. If the energy of the new state is lower than that of the old 
state, the new one is automatically accepted as the next step in docking. 
 
4.3.1.  Preparation of ligands and target protein tyrosine kinase  
The compounds involved in this study as ligands include 10-alkyl-2-deoxo-2-methylthioflavin-5-oxides (2), 
2-dimethylaminoalloxazine (3), 10-alkyl-2-alkylamino-2-deoxoflavin-5-oxides (4), 10-alkylflavins (5), 
7-methoxy-10-methylflavin-5-oxide (6), 2-alkylamino-2-deoxo-10-methyl-5-deazaflavins (8), 
2-alkylamino-2-deoxo-10-methylflavin-5-oxides (9), 2-methylthio-2-deoxo-5-deazaalloxazines (12), 
2-deoxo-2-methylthioalloxazine-5-oxides (13), 2-alkylamino-2-deoxo-5-deazaalloxazines (14), 2-alkylamino-2- 
deoxoalloxazines (15), and 3-alkyl-2-deoxo-2-methylthioalloxazine-5-oxides (16) were studied for their binding 
activities into PTK. The three dimensional structures of the aforementioned compounds were constructed using 
Chem 3D ultra 8.0 software [Chemical Structure Drawing Standard; Cambridge Soft corporation, USA (2003)], 
then they were energetically minimized by using MOPAC with 100 iterations and minimum RMS gradient of 0.10. 
 29 
The Gasteiger-Hückel charges of ligands were assigned. The crystal structures of c-Kit receptor protein-tyrosine 
kinase in complex with STI-571 (Imatinib or Gleevec) was retrieved from the RCSB Protein Data Bank 
http://www.rcsb.org/pdb/Welcome.do (PDB code: 1t46)27 accessed on April 4, 2006. All bound waters, ligand 
were removed from the protein and the polar hydrogens and the Kollman-united charges were added to the proteins. 
The amino acids of the ligand-target binding site were defined using data in pdbsum 
http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/ accessed on June 10, 2006.  
 
4.3.2.  Molecular modeling and analysis of the docked results 
The predicted binding free energy that includes the intermolecular energy and torsional free energy was used as the 
criterion for ranking. Furthermore, the intermolecular hydrogen bonds, whose effect has already been counted in the 
binding energy, were also investigated in order to find useful information for drug design. A comparison of the 
results suggests that the binding free energy is more reliable as a criterion for the virtual screening via molecular 
docking. Cluster analysis was performed on the docked results using a root mean square (RMS) tolerance of 0.5 Å. 
Each of the clusters that exhibited significant negative interaction energies was examined by Accelrys, DS modeling 
1.7 [Accelrys Inc., San Diego CA (2006)] to determine their binding orientations, molecular modeling, evaluation of 
the hydrogen bonds and for measuring RMSD, which was measured as distance between the centroids of the docked 
inhibitor and the native ligand. The mode of interaction of the native ligand (STI-571) within the crystal structure of 
c-Kit receptor protein-tyrosine kinase was used as a standard docked model as well as for RMSD calculation. 
Regarding the hydrogen bond interaction, the more linear hydrogen bond is likely to be more stronger.29 Therefore, 
in our modeling results we consider the hydrogen bond angle within about 120° to be of a reasonable strength.  
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